BRIEF—Takeda launches Entyvio for ulcerative colitis in Japan

Takeda Pharmaceutical has launched Entyvio (vedolizumab) for the treatment of patients with moderately to severely active ulcerative colitis (UC) in Japan.

The firm won Japanese approval this indication in July, based on the results from the Phase III study CCT-101, as well as data from the global GEMINI 1 trial.

Director Masato Iwasaki said: “Entyvio has been approved in more than 60 countries worldwide and has a robust clinical and real-world evidence base.”

"Takeda is pleased to provide healthcare providers and patients with an important new treatment option for ulcerative colitis and continue our mission of delivering innovative medicines for patients living with gastrointestinal diseases.”